These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3327106)

  • 61. Disorder of cellular immunity in pemphigus vegetans.
    Hornstein OP; Djawari D; Lukaschek E; Deinlein E
    Acta Derm Venereol; 1980; 60(2):135-38. PubMed ID: 6155019
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dissociation between allergy and immunity in leprosy.
    Curtis J; Turk JL
    Practitioner; 1983 Feb; 227(1376):vii-ix. PubMed ID: 6866907
    [No Abstract]   [Full Text] [Related]  

  • 63. Cellular immunity and its regulation in SLE.
    Alarcón-Segovia D
    Clin Rheum Dis; 1982 Apr; 8(1):63-75. PubMed ID: 6214366
    [No Abstract]   [Full Text] [Related]  

  • 64. Old age and immunity.
    Binette JP
    Prim Care; 1982 Mar; 9(1):7-13. PubMed ID: 6978498
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rifampicin in the treatment of reactions in leprosy.
    Rampen F
    Lepr Rev; 1976 Mar; 47(1):75-6. PubMed ID: 1263737
    [No Abstract]   [Full Text] [Related]  

  • 66. Hypersensitivity and immunity reactions and classification. editorial.
    Ridley DS
    Lepr Rev; 1976 Sep; 47(3):171-4. PubMed ID: 787708
    [No Abstract]   [Full Text] [Related]  

  • 67. Cell mediated immune status in brain tumour patients.
    Sharma R; Mohanty S; Tandon SC; Tiwari VD; Gupta RM
    Indian J Cancer; 1984; 21(2):75-8. PubMed ID: 6530233
    [No Abstract]   [Full Text] [Related]  

  • 68. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Mechanisms of the expression of cell-mediated immunity: cells and mediators involved in cell-mediated immunity (author's transl)].
    Katsura Y
    Rinsho Byori; 1980 Nov; 28(11):1068-74. PubMed ID: 7017201
    [No Abstract]   [Full Text] [Related]  

  • 70. [Reverse or inverse reaction - a present-day point].
    Carayon A
    Hansenol Int; 1981 Jun; 6(1):10-8. PubMed ID: 6749678
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Therapeutic effect of rifampicin (RFP) on leprosy. II. On the changes of the morphological index of M. leprae in patients (author's transl)].
    Ozawa T
    Repura; 1974; 43(1):26-34. PubMed ID: 4610308
    [No Abstract]   [Full Text] [Related]  

  • 72. Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients.
    Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
    J Med Assoc Thai; 1996 Apr; 79(4):210-7. PubMed ID: 8708505
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Whatever happened to cell-bound antibodies? On the overriding influence of dogma.
    Silverstein AM
    Nat Immunol; 2002 Feb; 3(2):105-8. PubMed ID: 11812981
    [No Abstract]   [Full Text] [Related]  

  • 74. Theophylline-sensitive and theophylline-resistant E-rosette-forming cells in leprosy.
    Dang DT; Pham MH; Hoang TL; Nguyen HH; Phan LT; Wright EP
    Int J Lepr Other Mycobact Dis; 1984 Jun; 52(2):251-3. PubMed ID: 6609894
    [No Abstract]   [Full Text] [Related]  

  • 75. [Immunopathogenesis of periodontal disease. Delayed hypersensitivity or polyclonal lymphocyte activation?].
    Valletta GC; Sbordone L
    Minerva Stomatol; 1981; 30(6):467-74. PubMed ID: 7035859
    [No Abstract]   [Full Text] [Related]  

  • 76. Rosette-forming cells in patients with treated leprosy.
    Dang DT; Pham MH; Hoang TL; Lai VG; Nguyen HH
    Int J Lepr Other Mycobact Dis; 1983 Jun; 51(2):174-8. PubMed ID: 6684644
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of cell-mediated immunity on leprosy patients in Taiwan: a preliminary report.
    Liu MF; Wang CR; Chen MY; Cheng CS
    Taiwan Yi Xue Hui Za Zhi; 1988 Jun; 87(6):622-5. PubMed ID: 3262712
    [No Abstract]   [Full Text] [Related]  

  • 78. Immunohistological analysis of skin reaction to My1 derived from Mycobacterium leprae.
    Narayanan RB; Ramu G; Malaviya GN; Sinha S; Sengupta U
    Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):46-51. PubMed ID: 3519804
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Systemic immunological reactivity in the absence of delayed type hypersensitivity during murine leprosy.
    Poulter LW
    Cell Immunol; 1978 Sep; 40(1):117-27. PubMed ID: 699066
    [No Abstract]   [Full Text] [Related]  

  • 80. Rifampicin in renal transplant.
    Rao SP; Rajasekar M; Ravichandran R
    J Assoc Physicians India; 1990 Oct; 38(10):822. PubMed ID: 2084108
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.